A Clinical Trial to Assess the Safety of SOR102 in Healthy Participants and Patients with Ulcerative Colitis

2023-510324-77-00 Protocol SOR102-101 Human pharmacology (Phase I) - First administration to humans Ended

Start 20 Oct 2024 · End 22 Oct 2024 · Status Ended · 2 EU/EEA countries · 7 sites · Protocol SOR102-101

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ended
Participants planned 18
Countries 2
Sites 7

Ulcerative colitis

Key facts

Sponsor
Sorriso Pharmaceuticals Inc.
Participant type
Patients
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Digestive System Diseases [C06]
Trial duration
20 Oct 2024 → 22 Oct 2024
Decision date (initial)
2024-06-17
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2023-510324-77-00
ClinicalTrials.gov
NCT06080048

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Ulcerative colitis

VersionLevelCodeTermSystem organ class
20.1 LLT 10045365 Ulcerative colitis 10017947

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Sorriso Pharmaceuticals Inc.

Sponsor organisation
Sorriso Pharmaceuticals Inc.
Address
9295 South 1300 East Suite 3
City
Sandy
Postcode
84094-3127
Country
United States

Scientific contact point

Organisation
Sorriso Pharmaceuticals Inc.
Contact name
Sara Barbat

Public contact point

Organisation
Sorriso Pharmaceuticals Inc.
Contact name
Sara Barbat

Locations

2 EU/EEA countries · 7 investigational sites

By country

CountryMS statusPlanned subjectsSites
Bulgaria Ended 2 1
Poland Ended 7 6
Rest of world
Georgia, Ukraine, United Kingdom
9

Investigational sites

Bulgaria

1 site · Ended
Multiprofile Hospital for Active Treatment Sveta Sofia
Gastroenterology, Bulevard Bilgariya 104, 1404, Sofiya

Poland

6 sites · Ended
Niepubliczny Zaklad Opieki Zdrowotnej VIVAMED Jadwiga Miecz
Poradnia gastroenterologiczna, Ul. Zamiejska 17, 03-580, Warszawa
Planetmed Sp. z o.o.
Gastroenterologia, Ul. Lubinowa 12/8, 52-210, Wroclaw
Vita Longa Sp. z o.o.
Badań Klinicznych, Ul. Uniczowska 6, 40-748, Katowice
Medical Network Sp. z o.o.
WIP Warsaw IBD Point Profesor Kierkuś, Ul. Plowiecka 103, 04-501, Warsaw
Bodyclinic Sp. z o.o. sp.k.
Klinika Gastroenterologii i Chorób Wewnętrznych, Ul. Ulica Jozefa Sierakowskiego 4/u3, 03-712, Warsaw
Endoskopia Sp. z o.o.
Gastroenterologia, Ul. Boleslawa Chrobrego 6/8, 81-756, Sopot

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Bulgaria 2024-10-20 2024-10-20
Poland 2024-10-20 2024-10-21

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-02-21 Poland Acceptable with conditions
2024-06-10
2024-06-14
2 SUBSTANTIAL MODIFICATION SM-1 2024-07-01 Poland Acceptable
2024-09-02
2024-09-06